A novel bispecific antibody targeting tumor necrosis factor α and ED-B fibronectin effectively inhibits the progression of established collagen-induce arthritis

Journal of Biotechnology

Volumn 186, Issue , 2014, Pages 1-12

  Liu, Mengyuan ^a,b   Xie, Mian ^a,b   Jiang, Sijing ^a,b   Liu, Guoping ^c   Li, Lujun ^a,b   Liu, Dongxu ^a,b   Yang, Xiaosong ^a,b  

^a HUBEI UNIVERSITY   (China)

^b Hubei Collaborative Innovation Center for Green Transformation of Bio Resources   (China)

^c YANGTZE UNIVERSITY   (China)

Author keywords

Bispecific antibody; ED B containing fibronectin; Pharmacokinetics; Rheumatoid arthritis; Tumor necrosis factor (TNF )

Indexed keywords

DISEASES; ESCHERICHIA COLI; GLYCOPROTEINS; MACROPHAGES; MAMMALS; PHARMACOKINETICS;

BIOLOGICAL AGENTS; BISPECIFIC DIABODY; CHRONIC INFLAMMATORY DISEASE; COLLAGEN-INDUCED ARTHRITIS; ED-B-CONTAINING FIBRONECTIN; RHEUMATOID ARTHRITIS; THERAPEUTIC EFFICACY; TUMOR NECROSIS FACTORS; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODIES; PHARMACOKINETICS;

ANTIRHEUMATIC AGENT; BISPECIFIC ANTIBODY; BISPECIFIC DIABODY; COLLAGEN; ED B FIBRONECTIN; FIBRONECTIN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ED B CONTAINING FIBRONECTIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BSDB; MONOCLONAL ANTIBODY TNF SCFV; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; CYTOKINE; FN1 PROTEIN, HUMAN; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; BIOLOGICAL ACTIVITY; CELL INCLUSION; CONTROLLED STUDY; DISEASE COURSE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG RETENTION; DRUG SPECIFICITY; ESCHERICHIA COLI; IN VITRO STUDY; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN TARGETING; SYNOVIUM; ANTIGEN BINDING; ANTIGEN RETRIEVAL; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG PURIFICATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; RHEUMATOID ARTHRITIS; TREATMENT DURATION; AMINO ACID SEQUENCE; ANIMAL; ARTHRITIS, EXPERIMENTAL; CHEMISTRY; FOOT; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; PROTEIN ENGINEERING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BISPECIFIC; ARTHRITIS, EXPERIMENTAL; BASE SEQUENCE; CELL LINE, TUMOR; CYTOKINES; DISEASE PROGRESSION; FIBRONECTINS; FOOT; MICE; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904262338     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2014.06.017     Document Type: Article

References (41)

1. Campbell I.K., Roberts L.J., Wicks I.P. Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. Immunol. Cell Biol. 2003, 81:354-366.
2. Stokkers P.C., Hommes D.W. New cytokine therapeutics for inflammatory bowel disease. Cytokine 2004, 28:167-173.
3. Tobin A.M., Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005, 19:47-57.
4. Van den Bosch F., Kruithof E., De Vos M., De Keyser F., Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000, 356:1821-1822.
5. Olsen N.J., Stein C.M. New drugs for rheumatoid arthritis. N. Engl. J. Med. 2004, 350:2167-2179.
6. Choy E.H., et al. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) 2000, 39:1139-1146.
7. Tabrizi M., Bornstein G.G., Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2010, 12:33-43.
8. Rath T., et al. The immunologic functions of the neonatal Fc receptor for IgG. J. Clin. Immunol. 2013, 33(Suppl 1):S9-S17.
9. Curtis J.R., et al. Risk of hospitalized bacterial infections associated with biologic treatment among U.S. Veterans with Rheumatoid Arthritis. Arthritis Care Res. (Hoboken) 2014, 66(7):990-997.
10. Askling J., et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum. 2009, 60:3180-3189.
11. Rosenblum H., Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun. Rev. 2011, 10:563-568.
12. Sanz L., Blanco B., Alvarez-Vallina L. Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol. 2004, 25:85-91.
13. Cuesta A.M., Sainz-Pastor N., Bonet J., Oliva B., Alvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 2010, 28:355-362.
14. Colcher D., et al. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q. J. Nucl. Med. 1998, 42:225-241.
15. Bykerk V.P., et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann. Rheum. Dis. 2013, 1-8.
16. Carnemolla B., et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 1989, 108:1139-1148.
17. Borsi L., et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 2002, 102:75-85.
18. Borsi L., Castellani P., Risso A.M., Leprini A., Zardi L. Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett. 1990, 261:175-178.
19. Zardi L., et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 1987, 6:2337-2342.
20. Ffrench-Constant C., Van de Water L., Dvorak H.F., Hynes R.O. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J. Cell Biol. 1989, 109:903-914.
21. Castellani P., et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 1994, 59:612-618.
22. Moosmayer D., et al. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin. Cancer Res. 2006, 12:5587-5595.
23. Pini A., et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 1998, 273:21769-21776.
24. Sauer S., et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113:2265-2274.
25. Claudepierre P., et al. Increased Ed-B fibronectin plasma levels in spondyloarthropathies: comparison with rheumatoid arthritis patients and a healthy population. Rheumatology (Oxford) 1999, 38:1099-1103.
26. Vollmer S., et al. Extra domain B fibronectin as a target for near-infrared fluorescence imaging of rheumatoid arthritis affected joints in vivo. Mol. Imaging 2009, 8:330-340.
27. Kriegsmann J., et al. Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Rheumatol. Int. 2004, 24:25-33.
28. Trachsel E., et al. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res. Ther. 2007, 9:R9.
29. Schwager K., et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res. Ther. 2009, 11:R142.
30. Kamperidis P., et al. Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritis. Arthritis Rheum. 2011, 63(12):3758-3767.
31. Liu M., et al. One-step on-column purification and refolding of a single-chain variable fragment (scFv) antibody against tumour necrosis factor alpha. Biotechnol. Appl. Biochem. 2006, 43:137-145.
32. Liu M., et al. Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb. Biochem. J. 2007, 406:237-246.
33. Liu M., et al. A novel bivalent single-chain variable fragment (scFV) inhibits the action of tumour necrosis factor alpha. Biotechnol. Appl. Biochem. 2008, 50:173-179.
34. Sheehan K.C., Ruddle N.H., Schreiber R.D. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J. Immunol. 1989, 142:3884-3893.
35. Courtenay J.S., Dallman M.J., Dayan A.D., Martin A., Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980, 283:666-668.
36. Campo G.M., et al. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res. Ther. 2003, 5:R122-R131.
37. Chang S.K., Gu Z., Brenner M.B. Fibroblast-like synoviocytes in inflammatory arthritis pathology: the emerging role of cadherin-11. Immunol. Rev. 2010, 233:256-266.
38. Eichhorn M.E., Strieth S., Dellian M. Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist. Updat. 2004, 7:125-138.
39. Molthoff C.F., Pinedo H.M., Schluper H.M., Nijman H.W., Boven E. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer. Br. J. Cancer 1992, 65:677-683.
40. Ishihara K., Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002, 13:357-368.
41. Seckinger P., et al. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J. Immunol. 1990, 145:4181-4184.